Epileptic Disorders


Rational conversion from antiepileptic polytherapy to monotherapy Volume 5, numéro 3, September 2003

1. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-39.

2. Cockerell OC, Johnson AL, Sander JWAS et al. Remission of epilepsy results from the National General Practice Study of Epilepsy. Lancet 1995; 346: 140-4.

3. Mattson RH, Cramer JA, Collins JF and the Department of Veterans Affairs Epilepsy Cooperative Studies No 118 and No 264 Group. Prognosis for total control of complex partial and secondary generalized tonic-clonic seizures. Neurology 1996; 47: 68-76.

4. Sillanpaa M, Jalava M, Kaleva O, et al. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998; 338: 1715-22.

5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.

6. Deckers CLP, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387-94.

7. Chadwick D, Shaw M, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642-4.

8. Brodie MJ. Established anticonvulsants and the treatment of refractory epilepsy. Lancet 1990; 336: 350-4.

9. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy. A reappraisal. CNS Drugs 1995; 3: 194-208.

10. Hakkarainen H. Carbamazepine vs diphenylhydantoin vs their combination in adult epilepsy. Neurology 1980; 30: 354.

11. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982; 45: 1119-24.

12. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257-62.

13. Walker JE, Koon P. Carbamazepine versus valproate versus combined therapy for refractory partial complex seizures with secondary generalization. Epilepsia 1988; 29: 693.

14. Lindberger M, Alenius M, Frisen L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia 2000; 41: 1289-95.

15. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996; 313: 1169-74.

16. Perucca E. Trial duration and follow-up. Epilepsy Res 2001; 45: 123-7; discussion 129-31.

17. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368-76.

18. Albright P, Bruni J. Reduction in polypharmacy in epileptic patients. Arch Neurol 1985; 42: 797-9.

19. Callaghan N, O’Callaghan M, Duggan B, et al. Carbamazepine as a single drug in the treatment of epilepsy. J Neurol Neurosurg Psychiatry 1978; 41: 907-12.

20. Maheshwari MC, Padmini R. Role of carbamazepine in reducing polypharmacy in epilepsy. Acta Neurol Scan 1981; 64: 22-8.

21. Callaghan N, O’Dwyer R, Keating J. Unnecessary polypharmacy in patients with frequent seizures. Acta Neurol Scan 1984; 69: 15-9.

22. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-83.

23. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997; 38 (suppl 9): S21-31.

24. French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002; 43 (suppl 10): 3-27.

25. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology 1993; 43: 688-92.

26. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-92.

27. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018-25.

28. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001; 57: 864-71.

29. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54: 2245-51.

30. Sachdeo RC, Reife RA, Lim P, et al. Topiramate monotherapy for partial-onset seizures. Epilepsia 1997; 38: 294-300.

31. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondary generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997; 49: 746-52.

32. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995; 36 (suppl 6): S2-S6.

33. Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 2003; 60 (11 Suppl 4): S13-25.

34. Stephen SJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002; 11: 349-51.

35. Deckers CLP. Overtreatment in adults with epilepsy. Epilepsy Res 2002; 52: 43-52.

36. Holmes GL. Overtreatment in children with epilepsy. Epilepsy Res 2002; 52: 35-42.

37. Ferrendelli JA. Use of rational polypharmacy to treat epilepsy. Epilepsy Res 1996; 11: 239-43.

38. Perucca E, Levy R Combination therapy and drug interactions. In: Antiepileptic drugs. 5th edition, Levy R, Mattson R, Meldrum B, Perucca eds, 2002, Lippincott Williams and Wilkin pp. 96-102.

39. Brodie MJ, Yuen AWC and the 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate ? Epilepsy Res 1997; 26: 423-32.

40. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6.

41. Anderson G, Gidal B, Messenheimer J, et al. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002; 49: 211-7.

42. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002; 43: 691-6.


Seizure type

Level of evidence

Side effect